Abilify Maintena (aripiprazole) for Extended-release Injectable Suspension, for Intramuscular Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

January 2016

ADVERSE REACTIONS

Postmarketing Experience

addition of pathological gambling and hiccups

...

Source: Drugs.com - Labeling Changes - January 1, 2016 Category: Drugs & Pharmacology Source Type: alerts